Compare BUR & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | MDXG |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 530.2M |
| IPO Year | 2017 | 2007 |
| Metric | BUR | MDXG |
|---|---|---|
| Price | $4.50 | $3.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.58 | $9.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $413,360,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $104.62 | N/A |
| Revenue Next Year | N/A | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $3.59 | $3.03 |
| 52 Week High | $14.61 | $7.99 |
| Indicator | BUR | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 49.42 |
| Support Level | $4.42 | $3.45 |
| Resistance Level | $4.97 | $7.39 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 21.50 | 51.43 |
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.